| answer text |
<p>Gabapentin is authorised for the treatment of some forms of epilepsy, as well as
peripheral neuropathic pain. The product information for gabapentin, approved by the
Medicines and Healthcare products Regulatory Agency (MHRA), provides information to
support the prescribing of the medication including recommendations for dose, duration
of use, as well as gradual reduction when stopping. The product information includes
warnings about possible side effects.</p><p>The MHRA continuously monitors the safety
of gabapentin and ensures the product information reflects what is known about the
medicine and its side effects.</p>
|
 |
